IIPLA News
Friday, January 23, 2026

Novo Nordisk Faces Antitrust Lawsuit Over Alleged Monopoly on Victoza Diabetes Medication

The pharmaceutical giant is accused of unlawfully monopolizing the market for its diabetes drug Victoza, prompting legal action in the United States.

IIPLA News Deskanonymous access0 articles left this week
Novo Nordisk Faces Antitrust Lawsuit Over Alleged Monopoly on Victoza Diabetes Medication
Sign In To Continue

You have reached the guest article limit.

Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.

Novo Nordisk has been sued for allegedly monopolizing the diabetes drug Victoza, with claims that the company engaged in anticompetitive practices to maintain exclusive control over the market. The lawsuit highlights concerns about market dominance and access to essential diabetes treatments.
Share This Article
Ready-to-post copy includes the article link.

Novo Nordisk Faces Antitrust Lawsuit Over Alleged Monopoly on Victoza Diabetes Medication Novo Nordisk has been sued for allegedly monopolizing the diabetes drug Victoza, with claims that the company engaged in anticompetitive practices to maintain exclusive control over the market. The lawsuit highlights co... Read the full IIPLA article: https://iipla.org/news/novo-nordisk-faces-antitrust-lawsuit-over-alleged-monopoly-on-victoza-diabetes-medication

Related Coverage

Continue in the newsroom

Back to newsroom
PatentsGlobal

Broadfield Strengthens London Office with Two New Partners in Private Wealth and IP Law

Broadfield has appointed Sarah Sarwar and Ash von Schwan as partners in its London office, bolstering its private wealth and intellectual property capabilities. Sarwar brings expertise in estate planning and cross-border tax for high-net-worth clients, while von Schwan focuses on IP and technology transactions across…

Monday, June 15, 2026